Literature DB >> 16540910

Treatment of contralateral N0 neck in early squamous cell carcinoma of the oral tongue: elective neck dissection versus observation.

Young Chang Lim1, Jin Seok Lee, Bon Seok Koo, Se-Heon Kim, Young-Ho Kim, Eun Chang Choi.   

Abstract

OBJECTIVES/HYPOTHESIS: Prophylactic treatment of contralateral N0 neck in early squamous cell carcinoma (SCC) of the oral tongue is a controversial issue. The aim of this study was to analyze the rates of occult metastases and their prognostic effects in stage I and stage II SCC of the oral tongue, and to compare the results of elective neck dissection to observation of the contralateral N0 neck in the treatment of these patients. STUDY
DESIGN: Retrospective review.
METHODS: We reviewed the medical records of 54 patients who were treated at Severance Hospital from 1992 to 2003 and had been diagnosed with stage I or stage II SCC of the oral tongue and had not received prior treatment. All patients underwent an ipsilateral elective neck dissection simultaneously with the primary lesion. The management of the contralateral N0 necks involved "watchful waiting" in 29 patients and elective neck dissection in 25 patients. Surgical treatment was followed by radiotherapy in 20 patients. Of these, seven patients belonged to the "observation" group who did not receive contralateral elective neck dissection. The follow-up period ranged from 3 to 110 months, with a mean of 56.3 months. Data were analyzed using the Kaplan-Meier method, the log-rank test, and the chi(2) test.
RESULTS: Fifteen patients (28%, 15 of 54) had occult metastases. Of these, 14 patients (26%, 14 of 54) had ipsilateral pathologic metastases. The remaining case (4%, 1 of 25) had the only contralateral level II occult neck metastasis without ipsilateral metastasis. Disease recurred in 17 of 54 patients (31%). Of these, eight cases (47%, 8 of 17) had regional recurrences. All regional recurrences developed in the ipsilateral neck; there were no cases of contralateral neck recurrence. The 5-year actuarial disease-free survival rates were 82% for the "observation" group and 68% for the elective neck dissection group. This difference was not statistically significant (P = .182). The 5-year actuarial disease-free survival rates were 83% for the "observation" group when those patients who underwent radiotherapy were excluded (n = 22) and 68% for the elective supraomohyoid neck dissection group (n = 25), which showed no statistically significant difference (P = .127).
CONCLUSIONS: This study showed that ipsilateral elective neck management is indicated for stage I and II SCC of the oral tongue. On the other hand, our series suggests that contralateral occult lymph node metastasis was unlikely in early-stage oral tongue SCC, and that there was no survival benefit for patients who underwent elective neck dissection in place of observation. Thus, it may not harmful to observe the contralateral N0 neck in the treatment of early oral tongue cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16540910     DOI: 10.1097/01.mlg.0000195366.91395.9b

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  25 in total

1.  Development of a Novel Markov Chain Model for the Prediction of Head and Neck Squamous Cell Carcinoma Dissemination.

Authors:  Hyunggu Jung; Anthony Law; Eli Grunblatt; Lucy L Wang; Aaron Kusano; Jose L V Mejino; Mark E Whipple
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

2.  Predictors of locoregional recurrence in T1-2N0 tongue cancer patients.

Authors:  Souichi Yanamoto; Shin-ichi Yamada; Hidenori Takahashi; Goro Kawasaki; Hisazumi Ikeda; Takeshi Shiraishi; Shuichi Fujita; Tohru Ikeda; Izumi Asahina; Masahiro Umeda
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

3.  Differentiation of benign and malignant lesions of the tongue by using diffusion-weighted MRI at 3.0 T.

Authors:  S Li; J Cheng; Y Zhang; Z Zhang
Journal:  Dentomaxillofac Radiol       Date:  2015-03-31       Impact factor: 2.419

4.  Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances.

Authors:  Xiqiang Liu; Antonia Kolokythas; Jianguang Wang; Hongzhang Huang; Xiaofeng Zhou
Journal:  Curr Cancer Ther Rev       Date:  2010-11-01

5.  The prognostic importance of midline involvement in oral tongue cancer.

Authors:  Shane Lloyd; James B Yu; Lynn D Wilson; Benjamin L Judson; Roy H Decker
Journal:  Am J Clin Oncol       Date:  2012-10       Impact factor: 2.339

6.  Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution.

Authors:  Aviram Mizrachi; Jocelyn C Migliacci; Pablo H Montero; Sean McBride; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2018-02-20       Impact factor: 5.337

7.  Predictive Significance of Tumor Depth and Budding for Late Lymph Node Metastases in Patients with Clinical N0 Early Oral Tongue Carcinoma.

Authors:  Yukiko Hori; Akira Kubota; Tomoyuki Yokose; Madoka Furukawa; Takeshi Matsushita; Morihito Takita; Sachiyo Mitsunaga; Nobutaka Mizoguchi; Tetsuo Nonaka; Yuko Nakayama; Nobuhiko Oridate
Journal:  Head Neck Pathol       Date:  2017-04-03

8.  Is there a role for neck dissection in T1 oral tongue squamous cell carcinoma? The UCLA experience.

Authors:  Kevin A Peng; Alan C Chu; Chi Lai; Tristan Grogan; David Elashoff; Elliot Abemayor; Maie A St John
Journal:  Am J Otolaryngol       Date:  2014-07-10       Impact factor: 1.808

9.  Patients with unilateral squamous cell carcinoma of the tongue and ipsilateral lymph node metastasis do not profit from bilateral neck dissection.

Authors:  Christoph Klingelhöffer; Andreas Gründlinger; Gerrit Spanier; Stephan Schreml; Maximilian Gottsauner; Steffen Mueller; Johannes K Meier; Torsten E Reichert; Tobias Ettl
Journal:  Oral Maxillofac Surg       Date:  2018-03-29

10.  Cervical metastases of squamous cell carcinoma of the maxilla: a retrospective study of 9 years.

Authors:  Astrid L D Kruse; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.